Heat shock protein 22 (HSP22) is ubiquitously expressed in various types of cells including in osteoblasts. We previously reported that tumor necrosis factor (TNF)-a stimulates interleukin (IL)-6 synthesis via p44/p42 MAPK in osteoblast-like MC3T3-E1 cells and that mTOR/p70 S6 kinase (p70 S6K) negatively regulates the IL-6 synthesis. In this study, we investigated the involvement of HSP22 in TNF-a-stimulated-IL-6 synthesis and the underlying mechanism in MC3T3-E1 cells. HSP22 knockdown reduces TNF-a-stimulated release of IL-6. In addition, HSP22 knockdown strengthens TNF-ainduced phosphorylation of p70 S6K but suppresses that of p44/p42 MAPK. HSP22 coimmunoprecipitates with mTOR. HSP22 knockdown increases the basal levels of phosphorylated mTOR. These results strongly suggest that HSP22 interacts with mTOR and regulates TNF-a-induced IL-6 synthesis in osteoblasts.
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Keywords: HSP22; mTOR; osteoblast Heat shock proteins (HSPs) as molecular chaperones possess cytoprotective activities and increase tolerance to various unfavorable circumstances including physiological stresses in cells [1] . The HSP family is currently categorized into seven groups, namely HSPA (HSP70), HSPB (small HSP), HSPC (HSP90), HSPD/E (HSP60/ HSP10), HSPH (HSP110), DNAJ (HSP40) and CCT (TRiC) [1, 2] . Small HSPs (HSPBs) have low molecular mass in the range of 12-43 kDa, and 10 small HSPs (HSPB1-HSPB10) are identified based on human genome [3, 4] . Small HSPs have a highly conserved a-crystallin domain consisting of about 90 amino acids [5, 6] . Among 10 members, HSP27, aB-crystallin, HSP20 and HSP22 are ubiquitously expressed in variety type of tissues [1] . In addition to chaperone activity, accumulating evidence indicates that small HSPs are involved in various physiological and pathological processes including vasoconstriction and cancer [1] .
Among small HSPs, HSP22 (HSPB8) that has been first detected in human melanoma cells is highly expressed in skeletal and smooth muscle, heart and brain [7] [8] [9] . It has been shown that the dysfunction of HSP22 causes some kinds of neuromuscular diseases such as distal hereditary motor neuropathy and axonal Charcot-Marie-Tooth disease [10, 11] . In addition, HSP22 is reportedly implicated in proliferation and antiapoptotic activity in cancer cells such as glioblastoma, melanoma and breast cancer [12, 13] . We have previously demonstrated that HSP22 is expressed in human ovarian cancer cells, and enhances the transforming growth factor (TGF)-a-induced cell migration [14] . In our recent study [15] , we have shown that Abbreviations HSPs, heat shock proteins; IL, interleukin; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; TGF, transforming growth factor.
HSP22 directly interact with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma cells, and regulate the cell proliferation and the migration. However, the precise role of HSP22 remains to be clarified.
Metabolism of bone tissue in the skeleton is strictly designated by two types of effector cells, osteoblasts and osteoclasts [16] . The former cells contribute to bone formation, whereas the latter cells are responsible for bone resorption. In order to maintain the stability of bone and the integrity, bone tissue is constantly reconstructed by a sequential process consisted of the resorption of old bone and the formation of new bone, so called bone remodeling [17] . It is well recognized that various humoral factors including cytokines participate in and maintain the bone homeostasis [18] . It has been shown that increased inflammatory cytokines such as tumor necrosis factor (TNF)-a and interleukin (IL)-1 promote bone resorption [19] . In osteoblasts, accumulating evidence indicates that bone resorptive agents including TNF-a, stimulate the production of IL-6, leading to the upregulation of osteoclastgenesis and bone resorption [19] [20] [21] [22] . As for the intracellular signaling of TNF-a in osteoblasts, we have previously reported that TNF-a stimulates IL-6 synthesis via activation of the p44/p42 mitogen-activated protein kinase (MAPK) in osteoblasts-like MC3T3-E1 cells and that mTOR/p70 S6 kinase (p70 S6K) act as negative regulators in the IL-6 synthesis at a point upstream of p44/ p42 MAPK [23] [24] [25] . Regarding HSP22 in osteoblasts, we have recently shown that HSP22 exists in MC3T3-E1 cells and regulates the cell migration stimulated by TGF-b [26] . However, the details of HSP22 in osteoblasts have not yet been elucidated.
In the present study, we investigated the implication of HSP22 in the TNF-a-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells. We herein show that HSP22 is directly associated with mTOR in MC3T3-E1 cells, resulting in regulating the TNF-a-induced IL-6 synthesis through p70 S6K. 
Materials and methods

Materials
Cell culture
Cloned osteoblast-like MC3T3-E1 cells derived from newborn mouse calvaria [27] were maintained as described previously [28] . In summary, the cells were cultured in a-MEM containing 10% FBS. The cells were seeded into 35-or 90-mm diameter dishes and incubated at 37°C in a humidified atmosphere of 5% CO 2 /95% air for indicated periods.
siRNA transfection
To knockdown HSP22 in MC3T3-E1 cells, the cells were transfected with HSP22-siRNA (#1 and #2) or negative control siRNA (Neg) using siLentFect Lipid Reagent (BioRad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's instruction. The cells were incubated with 50 nM siRNA-siLentFect complexes for 24 h at 37°C. The medium was exchanged to a-MEM containing 0.3% FBS before experiments.
ELISA for IL-6
The siRNA-transfected cells were stimulated by 30 ngÁmL À1 TNF-a or vehicle. The conditioned medium was collected after 48 h, and the IL-6 concentration was measured using a mouse IL-6 ELISA kit according to the manufacturer's instructions.
Western blot analysis
The transfected cells were stimulated by 30 ngÁmL À1 TNFa or vehicle for the indicated periods. The cells were then lysed, homogenized and sonicated in a lysis buffer containing 62.5 mM Tris/HCl (pH 6.8), 2% SDS, 50 mM dithiothreitol and 10% glycerol. SDS-PAGE was performed by the method of Laemmli [29] . The proteins were fractionated and transferred onto an Immun-Blot PVDF membrane (Bio-Rad). A western blot analysis was performed as previously described [30] using the indicated primary antibodies with peroxidase-labeled antibodies as secondary antibodies. The peroxidase activity on the PVDF sheet was visualized on X-ray film by means of the ECL western blotting detection system.
Coimmunoprecipitation
Coimmunoprecipitation was performed as described previously [8] . Briefly, the cells were lysed in TNE lysis buffer (10 mM Tris-HCl, pH 7.8, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM sodium fluoride, 1 mM sodium vanadate and protease inhibitors cocktail; Roche Diagnostics K.K., Basel, Switzerland). The lysates were then centrifuged at 100 000 g at 4°C for 30 min, and the supernatant was collected as TNE-soluble proteins. The HSP22 antibodies or normal rabbit IgG (Cell Signaling Technology, Inc.) were added to the TNE-soluble proteins, and the mixture was shaken gently through the overnight at 4°C. Protein immunocomplexes were isolated using Dynabeads protein A (Life Technologies Corp., Carlsbad, CA, USA). The immunoprecipitated proteins were analyzed by a western blot analysis using p70 S6K antibodies, mTOR antibodies or HSP22 antibodies as primary antibodies.
Densitomtric analysis
The densitometric analysis was performed using a scanner and IMAGE ANALYSIS software package (imageJ version 1.48; NIH, Bethesda, MD, USA). The phosphorylated protein levels were calculated as follows: the background-subtracted signal intensity of each phosphorylation signal was normalized to GAPDH signal, and plotted as the fold increase in comparison with that of the control cells without stimulation.
Statistical analysis
The data were analyzed by analysis of variance followed by the Bonferroni method for multiple comparisons between pairs. The values of P < 0.05 were considered to be statistically significant. Each data are presented as the mean AE SEM of triplicate determinations from three independent cell preparations.
Results
Effect of TNF-a-on the IL-6 release from HSP22-knockdown MC3T3-E1 cells
We have demonstrated that TNF-a stimulates the IL-6 synthesis in osteoblast-like MC3T3-E1 cells [23] . To investigate whether HSP22 is involved in the IL-6 synthesis in MC3T3-E1 cells, we first examined the effect of HSP22-siRNA on the TNF-a-stimulated release of IL-6. We confirmed that the HSP22 protein levels in MC3T3-E1 cells were significantly reduced by the transfection of HSP22-siRNA (#1 and #2), and found that the effect of HSP22-siRNA (#2) on HSP22 protein levels was more potent than that of HSP22-siRNA (#1) (Fig. 1A) . The TNF-a-stimulated IL-6 release was significantly suppressed by the transfection of HSP22-siRNA (#1 and #2) (Fig. 1B) . HSP22-siRNA (#2) more effectively reduced the TNF-a-induced IL-6 release than HSP22-siRNA (#1), correlated with the protein levels of HSP22.
TNF-a-induced phosphorylation of p70 S6K or p44/p42 MAPK in HSP22-knockdown MC3T3-E1 cells
We previously showed that TNF-a induces the synthesis of IL-6 through p44/p42 MAPK in osteoblast-like MC3T3-E1 cells while p70 S6K acts as a negative regulator at a point upstream of p44/p42 MAPK in the IL-6 synthesis [25] . In order to elucidate whether HSP22 affects the TNF-a-induced activation of p70 S6K in MC3T3-E1 cells, we examined the effect of HSP22 knockdown on the phosphorylation of p70 S6K induced by TNF-a. The basal levels of phosphorylated p70 S6K in the HSP22-siRNA-transfected cells were significantly enhanced [ Fig 
Association of HSP22 with p70 S6K and mTOR in MC3T3-E1 cells
To clarify how HSP22 regulates p70 S6K in osteoblast-like MC3T3-E1 cells, we examined whether HSP22 directly interacts with p70 S6K by a coimmunoprecipitation assay. However, the association of HSP22 with p70 S6K was not observed in MC3T3-E1 cells (data not shown). It is generally recognized that mTOR functions at a point upstream of p70 S6K [31] . We previously reported that rapamycin, an inhibitor of mTOR, which suppressed the TNF-a-induced phosphorylation of p70 S6K, enhanced the TNF-a-stimulated IL-6 synthesis in osteoblasts-like MC3T3-E1 cells [25] . Therefore, we next examined whether HSP22 associates with mTOR in MC3T3-E1 cells. mTOR proteins were obviously coimmunoprecipitated with HSP22 proteins (Fig. 3A,  lane 2) . We confirmed that mTOR proteins were never immunoprecipitated with normal rabbit IgG (Fig. 3A,  lane 1) . Furthermore, HSP22 proteins were truly coimmunoprecipitated with mTOR proteins (Fig. 3B,  lane 2) .
Phosphorylation of mTOR in HSP22-knockdown MC3T3-E1 cells
To further investigate the direct association of HSP22 to mTOR in MC3T3-E1 cells, we evaluated the levels of phosphorylated mTOR (Ser-2448) in the HSP22-knockdown cells. The phosphorylation levels of mTOR in the cells without stimulation of TNF-a were significantly upregulated by the transfection of HSP22-siRNA [ Fig. 3C (#1) and Fig. 3D (#2) ].
Discussion
In the present study, we demonstrated that HSP22 knockdown suppressed the TNF-a-stimulated IL-6 release in osteoblast-like MC3T3-E1 cells. We previously found that TNF-a upregulates the expression of IL-6 mRNA in these cells [32] . Regarding the intracellular signaling of TNF-a in osteoblasts, we have reported that p44/p42 MAPK plays a positive regulator in the TNF-a-induced IL 6 synthesis in MC3T3-E1 cells, whereas mTOR/p70 S6K limits the IL-6 synthesis at a point upstream of p44/p42 MAPK [25] . We showed here that the downregulation of HSP22 caused the enhancement of phosphorylated p70 S6K and the inhibition of phosphorylated p44/p42 MAPK in the TNF-a effects. Therefore, it is probable that HSP22 plays a suppressive role in TNF-a-induced p70 S6K activation, resulting in the regulation of p44/p42 MAPK in MC3T3-E1 cells. In addition, we found that HSP22 protein was coupled with mTOR but not with p70 S6K in these cells. Furthermore, the levels of phosphorylated mTOR were upregulated by HSP22 knockdown. It is generally known that mTOR activates p70 S6K in response to various stimuli [31] . Thus, it seems likely that that mTOR amplifies the Fig. 1 . Effect of HSP22 knockdown on the TNF-a-stimulated release of IL-6 in MC3T3-E1 cells. (A) The cells were transfected with 50 nM of HSP22-siRNA (#1 or #2) or negative control-siRNA (Neg) for 24 h, and the protein levels of HSP22 were detected by western blot analysis using antibodies against HSP22 or GAPDH. The histogram shows the quantification data of the protein levels of HSP22 after normalization with GAPDH determined by laser densitometry analysis. Each value represents the mean AE SEM of triplicate determinations. *P < 0.05 compared to the value of the negative control siRNA-transfected cells. (B) The transfected cells (#1, #2 and Neg) were stimulated by 30 ngÁmL À1 of TNF-a or vehicle for another 48 h. IL-6 concentrations in the conditioned medium were determined by ELISA. Each value represents the mean AE SEM of triplicate determinations from three independent cell preparations. *P < 0.05 compared to the value of negative control siRNA-transfected cells without TNF-a. **P < 0.05 compared to the value of the negative control siRNA-transfected cells with TNF-a. indicated antibodies. The histogram shows the quantification data of the phosphorylated levels after normalization with GAPDH levels determined by laser densitometry analysis. Each value represents the means AE SEM of triplicate determinations from three independent cell preparations. *P < 0.05 compared between the indicated pairs. **P < 0.05 compared to the value of negative control siRNAtransfected cells without TNF-a stimulation (lane 1). ***P < 0.05 compared to the value of HSP22-siRNA-transfected cells without TNF-a stimulation (lane 2).
TNF-a-induced p70 S6K activation when the function of HSP22 is inhibited, leading the suppression of p44/ p42 MAPK. Based on our findings, it is most likely that mTOR associated with HSP22 limits the p70 S6K activation in osteoblast-like MC3T3-E1 cells, resulting in the regulation of TNF-a-stimulated IL-6 synthesis via p44/p42 MAPK. To the best of our knowledge, this is probably the first report showing the direct association of HSP22 with mTOR. The potential mechanism of HSP22 in TNF-a-stimulated IL-6 synthesis in osteoblasts shown here is summarized as Fig. 4 . It is currently known that HSPs including HSP22 interact with other proteins as clients, and forms hetero-oligomeric complexes, resulting in modulating the client's functions in addition to chaperone-like activities [1, 33, 34] . In the present study, we demonstrated that HSP22 binds to mTOR and regulates its activity in osteoblast-like MC3T3-E1 cells. It is recognized that mTOR exists in two structurally different complexes, mTOR complex 1 and mTOR complex 2, and the activity of mTOR complex 1 directly affects to p70 S6K [35] . Tuberous sclerosis complex (TSC) reportedly directly interacts with mTOR complex 1 to negatively regulate its activity [36] . These findings suggest that HSP22 associates with mTOR complex 1, leading to the suppression of activity in osteoblast-like MC3T3-E1 cells. In addition, we herein demonstrated that the phosphorylation at Ser-2448 in mTOR was markedly strengthened by HSP22 knockdown in these cells. The amino acids sequence from 2430 to 2450 of mTOR including Ser-2448 reportedly functions as a repressor domain in mitogen-stimulated cells, which negatively regulates the catalytic activity of mTOR [37] . Thus, it is possible that HSP22 interacts with this repressor domain of mTOR, and causes conformational change in mTOR leading to the suppression of mTOR phosphorylation in MC3T3-E1 cells. However, it remains unclear how HSP22 binds to mTOR and forms complex with it in detail. Further investigations are needed The cell lysates were immunoprecipitated (IP) with HSP22 antibodies (lane 2) followed by western blotting (WB) using mTOR antibodies. The levels of total mTOR in preimmunoprecipitated cell lysates were also determined by WB (lane 3). (B) The cell lysates were immunoprecipitated (IP) with mTOR antibodies (lane 2) followed by WB using HSP22 antibodies. Immunoprecipitation of the lysate was confirmed using normal rabbit IgG (A, B; lane 1). The levels of total HSP22 in preimmunoprecipitated cell lysates were also determined by WB (lane 3). The cells were transfected with 50 nM of HSP22-siRNA (#1) (C), HSP22-siRNA (#2) (D) or negative control-siRNA (Neg) for 24 h, and then the cells were lysed and analyzed by western blotting with antibodies against phospho-specific mTOR (Ser-2448), mTOR, HSP22 or GAPDH. The histogram shows the quantification data of the phosphorylated mTOR levels after normalization with GAPDH levels determined by laser densitometry analysis. Each value represents the mean AE SEM of triplicate determinations from three independent cell preparations. *P < 0.05 compared to the value of negative control siRNA-transfected cells.
to elucidate the exact mechanism behind the suppression of mTOR by HSP22.
In osteoblasts, it has been shown that mTOR promotes their proliferation and differentiation [38] . Furthermore, rapamycin reportedly enables to induce the delay of fracture healing by inhibiting osteoblast proliferation in mice [39] , suggesting the critical role of mTOR in bone metabolism. In the present study, we showed that the TNF-a-induced IL-6 synthesis was suppressed by the upregulation of mTOR activity resulting from HSP22 knockdown in MC3T3-E1 cells. TNF-a and IL-6 are well known as potent bone resorptive agents, which synergistically stimulate osteoclast differentiation resulting in the promotion of bone resorption [40] . The chronic inflammation and following loss of bone density in rheumatoid arthritis (RA) are speculated to be caused mainly by TNF-a and IL-6 [19] . While, it has been reported that HSP22 exists abundantly in synovial tissue in RA [41] . Based on these findings, it seems that HSP22 possibly affects the IL-6 production and RA development. In addition, the inflammatory cytokines including IL-6 are recognized to play an important role in the pathogenesis of bone metabolic distress such as osteoporosis [42] . Taking these findings into account, the downregulation of HSP22 could be utilized to inhibit bone resorption through the reduction of IL-6 synthesis in osteoblasts, which may provide a treatment option for osteoporosis. Our findings in the present study show a novel insight into the function of HSP22 in osteoblasts. The phenotype experiments about bone resorption would be helpful to support our opinion. Further investigations are necessary to clarify the exact roles of HSP22 in osteoblasts.
In conclusion, our current findings strongly suggest that HSP22 directly interacts with mTOR and regulates the TNF-a-induced IL-6 synthesis via p70 S6K in osteoblasts. 
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